Page 4 - Vaccine

ICMR has collected over Rs 171 crore as royalty from Covaxin's sales: Govt

The ICMR has spent around Rs 35 crore in research and development of covid vaccine Covaxin

Vaccine sales pushes Pfizer beyond expectations in final quarter

Pfizer said Tuesday that it expects adjusted earnings in the new year to range from USD 6.35 to USD 6.55 per share on USD 98 billion to USD 102 billion in revenue

Covid vaccine: Single-dose Sputnik Light gets DCGI nod for emergency use

Sputnik V is a heterogeneous vaccine which uses two different components in its two doses

Centre places purchase order for 50 mn doses of Corbevax at Rs 145 apiece

The government is yet to decide on which segment of beneficiaries this new vaccine would be administered

Triple vaccinated can fight Omicron variant efficiently, study finds

The study, published recently in the journal Nature Medicine, tracked the antibodies of vaccinated and recovered individuals for two years

Exposure to one nasal droplet may be enough for Covid infection: Study

Among several key clinical insights, researchers found that symptoms start to develop very fast, on average about two days after contact with the virus

Reports saying 5 mn unused Covishield doses may go waste 'misleading': Govt

It said the Centre had proactively advised all state governments to review the availability of vaccines to ensure that the wastage of doses is reduced to a minimum

Covid symptoms appear in 2 days after virus exposure: Study

According to the World Health Organisation (WHO), Covid symptoms take around five to six days to appear after infection

What next for vaccines?

Budget numbers suggest govt reducing the scale

Pfizer applies to USFDA for two-dose vaccine for kids under 5 years

The request for emergency authorisation comes as the highly contagious Omicron variant has led to record numbers of infections

'Vaccines induce robust protection against severe disease from Omicron'

Current COVID-19 vaccines provide robust protection against severe disease and hospitalisation caused by both the Delta and Omicron variants, according to a study. The research, published in the journal Nature on Monday, demonstrated that the vaccines induce this protection through cellular immunity or the production of protective immune cells, such as so-called killer and memory cells. Cellular immunity continues to protect from severe COVID-19 disease despite the Omicron variant's evasion of neutralising antibodies, the researchers said. The team at Beth Israel Deaconess Medical Center (BIDMC) in Israel assessed samples from 47 individuals vaccinated with either the Johnson & Johnson or Pfizer-BioNTech vaccines. "Our data provide immunological context for the observation that current vaccines still provide robust protection against severe disease and hospitalisation due to the Omicron variant despite substantially reduced neutralising antibody responses and increased ...

Covid-19: Scientists debate over need for Omicron-specific vaccine

Several scientists have claimed that a Covid variant-specific vaccine is not needed, and that the existing shots are well effective against all variants, including Omicron

Covid vaccines administered in India cross 1.65-bn mark

With the administration of more than 56 lakh vaccine doses in the last 24 hours, India's Covid-19 vaccination coverage on Saturday exceeded 165.04 crore, as per the health ministry report

Multiple triggers across key markets may support Cipla's recent rally

In addition to the Q3 show, new launches offer upsides from current levels

Covishield, Covaxin prices likely to be capped at Rs 275 per dose

Additional Rs 150 could be service charge; regular market nod expected soon

Explained: How Omicron evades antibodies, remain contagious

An international team of scientists has determined the precise structural changes in the spike protein of the Omicron variant

Current Covid vaccines may protect from disease caused by Omicron: Study

Current COVID-19 vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 that can recognise variants of concern, including Omicron, and protect from severe disease, a study has found. The research, published in the journal Cell, also shows that fully vaccinated people have fewer memory B cells and neutralising antibodies against the Omicron variant. Both T and B cells play an important role in the immune response against an infection. Scientists at La Jolla Institute for Immunology (LJI) in the US tested four COVID-19 vaccines -- Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax. "The vast majority of T cell responses are still effective against Omicron," said study co-leader Alessandro Sette, a professor at LJI. "These cells won't stop you from getting infected, but in many cases they are likely to keep you from getting very ill," said co-author Shane Crotty, a professor at LJI. This is true in all the type of vaccines studied, and up to six months .

Pfizer, CornoaVac vaccine may cause heart inflammation in adolescents

Despite low risk, there is an increased relative risk of carditis - a type of heart inflammation - associated with Covid vaccine developed by Pfizer and China's CoronaVac, researchers have found.

Viral vaccines, vector platforms may become new growth areas: DRL chief

In a Q&A, the chairman of Dr Reddy's Laboratories dwells, among other things, on the draft R&D policy and the first-ever Global Innovation Summit of the pharma sector held last November

Market approval for Covishield, Covaxin likely to come with riders

Will the vaccines be freely available with chemists?